Biocon Limited announced the appointment of Shreehas Tambe as its new Chief Executive Officer & Managing Director, effective April 1, 2026. This transition aligns with the full integration of Biocon Biologics, creating a unified biopharma entity. Tambe, formerly CEO of Biocon Biologics, will lead the combined platform spanning biosimilars, generics, and peptides. Kedar Upadhye has been appointed as the new Chief Financial Officer.
Biocon Announces Key Leadership Transition
Biocon Limited confirmed today, March 27, 2026, the appointment of Shreehas Tambe as its Chief Executive Officer & Managing Director, commencing April 1, 2026. This appointment follows approvals from the Nomination & Remuneration Committee and the Board of Directors. As the first CEO of the integrated Biocon, Mr. Tambe will be responsible for leading the combined platform, which encompasses biosimilars and generics, aiming for enhanced global competitiveness and scale.
Strategic Rationale for Integration
This leadership change is central to the full integration of Biocon Biologics Limited as a wholly owned subsidiary of Biocon Limited. The resulting structure aims to create a unified enterprise well-positioned to lead in key therapeutic areas, including diabetes, obesity, oncology, and immunology, leveraging a portfolio that includes biosimilars, insulins, complex generics, and GLP-1 therapies.
Executive Statements on New Leadership
Kiran Mazumdar-Shaw, Executive Chairperson, expressed confidence in Mr. Tambe, noting his pivotal role in the transformation journey, including the acquisition and integration of the Viatris biosimilars business. Under his leadership, Biocon Biologics emerged as one of the world’s top five biosimilar companies with a valuation of USD 5.5 billion as of 2025. Ms. Mazumdar-Shaw also thanked the outgoing executive, Siddharth Mittal, for his significant contributions, noting his transition to another leadership role within the Biocon Group.
Shreehas Tambe stated that his focus will be on strengthening the foundation, consolidating the business, and accelerating sustainable growth for the leading global medicines company.
New Chief Financial Officer Appointed
In a related announcement, Kedar Upadhye has been appointed as the new Chief Financial Officer of Biocon Limited.
Profile of Shreehas Tambe
Mr. Tambe joined Biocon nearly three decades ago. As CEO and Managing Director of Biocon Biologics, he successfully oversaw its rapid consolidation following the acquisition of Viatris’ biosimilars business. Earlier in his career, he led the worldwide expansion of the insulins business, establishing Asia’s largest integrated insulins facility in Malaysia. Mr. Tambe is an inventor on 61 patents and holds a Master’s degree in Bioprocess Technology. He is a recipient of multiple industry awards, including the Times Now Most Promising Business Leaders of Asia Award in 2026.
Biocon Limited Overview
Biocon Limited is highlighted as a global biopharmaceutical company focused on providing affordable medicines across chronic and non-communicable diseases. The company has commercialized 12 biosimilar products and 30+ generic formulations globally, supported by robust R&D focused on over 20+ biosimilar assets. Biocon operates in more than 120 countries with a workforce exceeding 9,500 employees and has been recognized in the S&P Global Sustainability Yearbook for the fourth consecutive year (2026).
Source: BSE
